Alternative splicing RNA interference MicroRNA siRNA shRNA Allele specific silencing Gene therapy Spinocerebellar ataxia type 6 (SCA6) is an inherited neurodegenerative disease caused by a polyglutamine (polyQ) expansion in the Ca V 2.1 voltage-gated calcium channel subunit (CACNA1A). There is currently no treatment for this debilitating disorder and thus a pressing need to develop preventative therapies. RNA interference (RNAi) has proven effective at halting disease progression in several models of spinocerebellar ataxia (SCA), including SCA types 1 and 3. However, in SCA6 and other dominantly inherited neurodegenerative disorders, RNAi-based strategies that selectively suppress expression of mutant alleles may be required. Using a Ca V 2.1 mini-gene reporter system, we found that pathogenic CAG expansions in Ca V 2.1 enhance splicing activity at the 3′end of the transcript, leading to a CAG repeat length-dependent increase in the levels of a polyQ-encoding Ca V 2.1 mRNA splice isoform and the resultant disease protein.
Introduction
Spinocerebellar ataxia type 6 (SCA6) is a debilitating form of ataxia in which cerebellar Purkinje neurons preferentially degenerate (Kordasiewicz and Gomez, 2007) . It is one of the most common forms of autosomal dominant cerebellar ataxia and one of nine inherited neurodegenerative diseases caused by a polyglutamine (polyQ)-encoding CAG repeat expansion (Williams and Paulson, 2008) . In SCA6, the expansion resides near the 3′end of the voltagegated P/Q-type calcium channel gene, Ca V 2.1 (CACNA1A). Despite a wealth of data describing Ca V 2.1 channel function (Pietrobon, 2010), it remains unclear how the polyQ expansion in Ca V 2.1 leads to SCA6. Consequently, efforts to design effective therapies for this currently untreatable disease have met with difficulty.
SCA6 shares pathological signatures with other polyQ disorders, such as intraneuronal protein aggregates and nuclear translocation of polyQ fragments (Ishiguro et al., 2010; Kordasiewicz et al., 2006; Kubodera et al., 2003; Seidel et al., 2009) . Two important features of SCA6, however, make it unique among the polyQ diseases. First, SCA6 is caused by a relatively small polyQ expansion in Ca V 2.1, only 20-33 glutamines in length (Kordasiewicz and Gomez, 2007; Zhuchenko et al., 1997) . In contrast, expansions of at least 35-38 glutamines are needed to cause disease in the other polyQ disorders. Second, unlike other polyQ disease proteins, only a subset of Ca V 2.1 isoforms contains the polyQ tract (Bourinet et al., 1999; Tsunemi et al., 2006) ; alternative splicing near the 3′end of Ca V 2.1 leads to the production of two distinct channel isoforms that either lack or contain the C-terminal polyQ tract ( Supplementary Fig. 1 ). These two variants are abundant in adult cerebellar Purkinje neurons where they are expressed at roughly equivalent levels and are thought to be functionally redundant (Kanumilli et al., 2006; Tsunemi et al., 2008; Watase et al., 2008) .
The clinical severity of polyQ disorders, including SCA6, is linked both to the size of the polyQ expansion and to the expression level of the protein harboring the expansion (Williams and Paulson, 2008) . Several groups including ours have used RNA interference (RNAi)
